Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary.
Losa F, Iglesias L, Pané M, Sanz J, Nieto B, Fusté V, de la Cruz-Merino L, Concha Á, Balañá C, Matías-Guiu X. Losa F, et al. Among authors: balana c. Clin Transl Oncol. 2018 Nov;20(11):1361-1372. doi: 10.1007/s12094-018-1899-z. Epub 2018 May 28. Clin Transl Oncol. 2018. PMID: 29808414 Free PMC article. Review.
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.
Roth P, Gorlia T, Reijneveld JC, de Vos F, Idbaih A, Frenel JS, Le Rhun E, Sepulveda JM, Perry J, Masucci GL, Freres P, Hirte H, Seidel C, Walenkamp A, Lukacova S, Meijnders P, Blais A, Ducray F, Verschaeve V, Nicholas G, Balana C, Bota DA, Preusser M, Nuyens S, Dhermain F, van den Bent M, O'Callaghan CJ, Vanlancker M, Mason W, Weller M. Roth P, et al. Among authors: balana c. Neuro Oncol. 2024 Sep 5;26(9):1670-1682. doi: 10.1093/neuonc/noae053. Neuro Oncol. 2024. PMID: 38502052 Free PMC article. Clinical Trial.
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.
Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C; Yondelis Ovarian Cancer Group. Del Campo JM, et al. Ann Oncol. 2009 Nov;20(11):1794-802. doi: 10.1093/annonc/mdp198. Epub 2009 Jun 25. Ann Oncol. 2009. PMID: 19556318 Free article. Clinical Trial.
Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
Lee MD, Patel SH, Mohan S, Akbari H, Bakas S, Nasrallah MP, Calabrese E, Rudie J, Villanueva-Meyer J, LaMontagne P, Marcus DS, Colen RR, Balana C, Choi YS, Badve C, Barnholtz-Sloan JS, Sloan AE, Booth TC, Palmer JD, Dicker AP, Flanders AE, Shi W, Griffith B, Poisson LM, Chakravarti A, Mahajan A, Chang S, Orringer D, Davatzikos C, Jain R; ReSPOND Consortium. Lee MD, et al. Among authors: balana c. Neuroradiology. 2023 Sep;65(9):1343-1352. doi: 10.1007/s00234-023-03196-9. Epub 2023 Jul 19. Neuroradiology. 2023. PMID: 37468750 Free PMC article.
The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation.
Gorria T, Crous C, Pineda E, Hernandez A, Domenech M, Sanz C, Jares P, Muñoz-Mármol AM, Arpí-Llucía O, Melendez B, Gut M, Esteve A, Esteve-Codina A, Parra G, Alameda F, Carrato C, Aldecoa I, Mallo M, de la Iglesia N, Balana C. Gorria T, et al. Among authors: balana c. Cancers (Basel). 2024 Feb 9;16(4):735. doi: 10.3390/cancers16040735. Cancers (Basel). 2024. PMID: 38398126 Free PMC article.
SEOM guideline for the treatment of malignant glioma.
Berrocal A, Gil M, Gallego Ó, Balaña C, Pérez Segura P, García-Mata J, Reynes G; SEOM (Spanish Society of Clinical Oncology). Berrocal A, et al. Among authors: balana c. Clin Transl Oncol. 2012 Jul;14(7):545-50. doi: 10.1007/s12094-012-0839-6. Clin Transl Oncol. 2012. PMID: 22721801
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Sepúlveda JM, Belda-Iniesta C, Gil-Gil M, Pérez-Segura P, Berrocal A, Reynés G, Gallego O, Capellades J, Ordoñez JM, La Orden B, Balañá C. Sepúlveda JM, et al. Among authors: balana c. Clin Transl Oncol. 2015 Sep;17(9):743-50. doi: 10.1007/s12094-015-1304-0. Epub 2015 Jun 2. Clin Transl Oncol. 2015. PMID: 26033428 Clinical Trial.
114 results